Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).

Keith T. Flaherty,Robert Gray,Alice P. Chen,Shuli Li,Lisa M. McShane,David Patton,Stanley R. Hamilton,P. Mickey Williams,A. John Iafrate,Jeffrey Sklar,Edith P. Mitchell,Lyndsay Harris,Naoko Takebe,David J. Sims,Brent Coffey,Tony Fu,Mark J. Routbort,James A. Zwiebel,Larry Rubinstein,Richard F. Little,Carlos L. Arteaga,Robert L. Comis,Jeffrey S. Abrams,Peter J. ODwyer,Barbara A. Conley,Nci Match team

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).

2020

PURPOSETherapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designe...

Keywords:

Oncology
Immunohistochemistry
antitumor activity
molecular analysis
Lung cancer
Internal medicine
Targeted therapy
Cancer
cancer clinical trial
Medicine
molecular targets

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations